For the detection of CMV in Saliva. Congenital CMV infection can be diagnosed by testing a newborn baby’s saliva, urine, or blood by CMV PCR. However, of the three specimen types that are recommended, only saliva is simple, noninvasive and easy to collect. Specimens must be collected for testing within 21 days after the baby is born in order to confirm a diagnosis of congenital CMV infection. Specimen collection should be performed at least 90 minutes (and preferably 120 minutes) post-breastfeeding.
CMV is a leading cause of permanent hearing loss in neonates (and/or of other important brain, vision and developmental problems). Early treatment with anti-viral medication like ganciclovir or valganciclovir (ideally within 1st month of life) improves outcomes and prevents further damage from hearing/vision loss.Procedure
Extraction of CMV DNA from saliva followed by amplification and detection using real-time, PCR. An internal control is added to ensure the extraction was performed correctly and the PCR reaction was not inhibited. Eurofins Viracor's assay design includes multiple targets to account for viral mutations, which significantly reduces the chance of false negative results. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.Specificity
The primers and probes used in this assay are specific for known CMV strains based on similarity search algorithms. Additionally, no cross reactivity was detected when tested against adenoviruses, BKV, EBV, HSV-1, HSV-2, HHV-6 variant A, HHV-6 variant B, HHV-7, HHV-8, JCV, parvovirus B19, SV-40, and VZV.
Same day (within 8 to 12 hours of receiving specimen), Monday through Saturday.
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Eurofins Viracor test requisition form must accompany each specimen. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.Causes for Rejection
- Samples from patients greater than 2 years old.
- Specimen types other than those listed including saliva samples not collected with swab as described above.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Eurofins Viracor's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.References
Barkai G, Ari-Even Roth D, Kuint J, et al. Universal neonatal cytomegalovirus screening using saliva – Report of clinical experience. Journal of Clinical Virology. August 1, 2014;60:361-366.
Demmler-Harrison G. Congenital Cytomegalovirus Infection. JAMA Pediatrics. December 2016;170(12):1142.
Grosjean J, Trapes L, Alain S, et al. Human cytomegalovirus quantification in toddler’s saliva from day care centers and emergency unit: A feasibility study. Journal of Clinical Virology. November 1, 2014;61:371-377.
Kadambari S, Luck S, Sharland M, et al. Evaluating the feasibility of integrating salivary testing for congenital CMV into the Newborn Hearing Screening Programme in the UK. European Journal Of Pediatrics. August 2015;174(8):1117-1121.
Ross S, Novak Z, Boppana S, et al. Mixed infection and strain diversity in congenital cytomegalovirus infection. The Journal of Infectious Diseases. October 1, 2011;204(7):1003-1007
Ross S, Ahmed A, Boppana S, et al. Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens. The Journal of Infectious Diseases. November 1, 2014;210(9):1415-1418.
Williams E, Kadambari S, Clark J, et al. Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Archives of Disease In Childhood. Fetal and Neonatal Edition. May 2014;99(3):F230-F236.